Browse Category

Pharmaceuticals 23 December 2025 - 27 December 2025

Septerna Shares (SEPN) Surge 23% Following Positive SEP-479 Signal, Exceeding Analyst Predictions
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson stock is heading into the final trading days of 2025 with U.S. markets closed for the weekend and year-end liquidity typically thinning across Wall Street. JNJ last closed at $207.63 on Friday, down 0.07% on the day, and was last indicated around $207.86 in after-hours trading, according to widely followed market data. Investing.com+1
27 December 2025
··
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

December 26, 2025 — GSK plc stock is closing out the year with a familiar mix of “defensive pharma stability” and “pipeline-driven volatility.” The past two weeks delivered a cluster of headline-worthy updates: a U.S. FDA approval for GSK’s twice-yearly asthma biologic, a high-profile U.S. drug-pricing agreement that directly touches GSK’s respiratory franchise, regulatory momentum for expanded vaccine use in Europe, and fresh competitive noise around Shingrix—one of GSK’s biggest profit engines.
26 December 2025
···
Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

December 25, 2025 — Even with U.S. markets closed for Christmas Day, Merck & Co., Inc. is ending 2025 as one of the most-watched large-cap pharma names on Wall Street. The stock closed at $106.45 on Wednesday, Dec. 24, and commentary published today points to a six-day winning streak that has pushed investors back into “what’s next” mode: how Merck replaces Keytruda’s eventual loss of exclusivity while navigating a shifting U.S. drug-pricing backdrop. Nasdaq
25 December 2025
·
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

December 25, 2025 — Merck & Co., Inc. is ending 2025 with something investors tend to enjoy: momentum with a story behind it. Even with U.S. markets closed for Christmas Day, Merck shares are in focus after a late-December climb that pushed the stock to fresh highs, helped along by a major Wall Street upgrade and a burst of pipeline and regulatory headlines. MarketBeat
25 December 2025
··
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

December 24, 2025 — Zai Lab Limited is back in the spotlight after a major regulatory catalyst in China helped lift sentiment around the biopharma name. The company announced that China’s National Medical Products Administration approved COBENFY for schizophrenia in adults—a decision that quickly rippled into trading on both its U.S. ADR and Hong Kong listings. Business Wire+1
24 December 2025
···
Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson is trading through a holiday-shortened Christmas Eve session with investors balancing a familiar mix of defensive appeal and headline risk. On Wednesday, December 24, 2025, J&J shares hovered around $207 in late-morning trade, keeping the healthcare bellwether close to its recent highs even as the company faces fresh legal scrutiny and renewed policy pressure on U.S. drug pricing. StockAnalysis
24 December 2025
···
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly and Company stock is in the spotlight on December 24, 2025 as investors digest a new round of GLP‑1 headlines that span regulatory momentum, global market expansion, and shifting coverage expectations—all of which feed directly into the long-term demand outlook for Lilly’s obesity and diabetes franchise.
24 December 2025
···
Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Dec. 24, 2025 — Novo Nordisk A/S has snapped back into the market’s spotlight this week after U.S. regulators cleared a pill version of its blockbuster obesity drug Wegovy—an approval that investors and analysts see as a pivotal moment in the fast-evolving GLP‑1 weight-loss race. But the story driving Novo Nordisk stock today is bigger than a single FDA decision: it’s also about pricing and coverage policy in the U.S., and a global expansion battle—especially in India—where branded GLP‑1s are colliding with the prospect of cheaper generics in 2026. Novo Nordisk+2Reuters+2
24 December 2025
···
Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Pharmaceutical Industries Limited stock is finishing 2025 with unusual momentum for a company long labeled “just a generics maker.” On Dec. 24, 2025, TEVA is trading around the $31–$32 range after a sharp run-up over the past several weeks, with holiday-thinned markets now digesting a cluster of developments that bulls say strengthen Teva’s “pivot to growth” story—and bears say risk turning into a valuation trap. StockAnalysis+1
24 December 2025
··
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals Holdings, Inc. is in the spotlight on December 24, 2025 after a sharp selloff driven by a major regulatory development: the U.S. Food and Drug Administration recommended that Reviva run an additional Phase 3 trial for its lead schizophrenia candidate, brilaroxazine, before filing a New Drug Application. SEC+1
24 December 2025
···
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates.
23 December 2025
····
1 … 30 31 32 33 34 … 47
Follow on Google News
Add as preferred source Open in Google News